OPULION
Journal / Investor: at AstraZeneca, cash flow before financing falls 37% and drops below the dividends paid

News · Investor AB

Investor: at AstraZeneca, cash flow before financing falls 37% and drops below the dividends paid

Over nine months, AstraZeneca's core earnings per share rose 14%, but the cash it generated before financing fell 37% to $4,301m, below the $4,955m of dividends paid. The holding is 7% of Investor's total assets at 30 September 2026. At the amount AstraZeneca intends to declare for the 2026 financial year, the year's dividend would be worth about $170m to Investor.

Core earnings per share
$8.00
Nine months 2026, up 14% year on year, AstraZeneca release of 30 October 2026, p. 1
Operating cash flow
$10,890m
Nine months 2026, against $12,233m a year earlier, or −11% (Opulion calculation), same release, p. 29
AstraZeneca at Investor
SEK 84,398m
7% of total assets at 30 September 2026, 3.3% of the capital, Investor interim management statement of 16 October 2026, p. 4

Why it matters for Investor shareholders: Investor holds 51,587,810 AstraZeneca shares, valued at SEK 84,398m at 30 September 2026 (p. 4). In the third quarter, before these accounts were published, the holding took SEK 9,115m off Investor's net asset value, for a total return of −9.6% (p. 6). Investor reports SEK 14,774m of dividends received from its listed companies over nine months, without a figure for AstraZeneca (p. 6). At the $3.30 per share that AstraZeneca intends to declare for the 2026 financial year (p. 24), its shares would bring in about $170m for the financial year (Opulion calculation: 51,587,810 × $3.30). The dividend that reaches Investor is paid in cash, and over nine months the cash AstraZeneca generated before financing covered only 87% of the dividends paid (Opulion calculation: 4,301 divided by 4,955).

The decline does not come from earnings. Core earnings, which the company calculates excluding amortisation and impairment of intangible assets, restructuring costs and other specified items, mainly acquisition-related (p. 19), reach $8.00 per share, and reported earnings per share rise 10% to $5.62 (p. 1). Operating cash flow, by contrast, falls from $12,233m to $10,890m. AstraZeneca attributes this $1,343m decrease mainly to movements in working capital and short-term provisions, including the impact of Farxiga's loss of exclusivity in the US, as well as higher tax paid and foreign exchange, offset by higher operating profit (p. 22). Working capital is the money tied up in inventories and receivables, net of operating payables. Its movement, together with short-term provisions, absorbed $1,730m of cash, after an inflow of $64m a year earlier, and tax paid rises from $2,193m to $2,634m (p. 29).

The second gap comes from investing cash flows: $6,589m of net outflows over nine months against $5,362m, including $3,862m of purchases of intangible assets, against $2,844m, and $600m of business acquisitions, against $60m (p. 29). The figures reconcile: 10,890 − 6,589 = $4,301m, the line the cash flow statement calls net cash inflow before financing activities, against $6,871m a year earlier, or −37% (Opulion calculation), when $4,968m of dividends had been paid (p. 29). Over the same period, AstraZeneca issued $4,972m of borrowings and repaid $2,456m (p. 29), and its net debt rose from $23,374m at 31 December 2025 to $25,833m at 30 September 2026 (p. 22).

AstraZeneca: cash flow before financing has fallen below the dividends paid
Nine months to 30 September 2025 and 2026, in millions of dollars. Cash flow statement in AstraZeneca's release of 30 October 2026, p. 29. Bars scaled to the largest.
Cash flow before financing, 2025
$6,871m
Dividends paid, 2025
$4,968m
Cash flow before financing, 2026
$4,301m
Dividends paid, 2026
$4,955m
In 2025, cash flow before financing exceeded the dividends paid. In 2026, it covers 87% of them (Opulion calculation).

This is neither a dividend cut nor a guidance downgrade: AstraZeneca reconfirms its 2026 total revenue and core earnings per share guidance at constant exchange rates, and its total revenue rises 8% over nine months to $46,881m (p. 1). Our analysis of 15 September concluded that the value of this holding for Investor would depend on what flows into AstraZeneca's revenue and cash flows: over nine months, revenue grows and operating cash flow falls. Investor's page details the other holdings in its portfolio.

WHAT THE COMPANY CONFIRMS

2026 guidance

Unchanged

Total revenue and core earnings per share at constant exchange rates, and an annual dividend the company intends to raise to $3.30 per share (p. 1 and 24).

WHAT ABSORBED THE CASH

Nine-month investing cash flows

$6,589m

Net outflows, including $3,862m of purchases of intangible assets and $600m of business acquisitions, against $5,362m a year earlier (p. 29).

WHAT WOULD REACH INVESTOR

Dividend intended for the 2026 financial year

About $170m

$3.30 per share on 51,587,810 shares (Opulion calculation), if the 2026 dividend were declared at that amount.

For Investor shareholders, two dates will decide. On 22 January 2027, Investor's year-end report will give the value of the holding at 31 December (statement of 16 October, p. 22). On 9 February 2027, AstraZeneca intends to publish its full-year results (release of 30 October, p. 5): they will show whether the fourth quarter brings cash flow before financing back to the level of the year's dividends, and at what amount the 2026 dividend is declared, and so what this holding will have brought Investor for the 2026 financial year.

Sources

Share this article